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PREVALENCE OF HUMAN HERPESVIRUS 8 ANTIBODIES IN THE POPULATION OF BELÉM,
PARÁ, BRAZIL
Ronaldo B. FREITAS, Maria Rute FREITAS & Alexandre C. LINHARES
SUMMARY
Serum samples from 497 children and adults inhabiting two neighbourhoods (Guamá and Terra Firme) in Belém, Pará, North
Brazil were screened for the presence of human herpesvirus 8 (HHV-8) antibody using an enzyme-linked immunosorbent assay. An
overall 16.3% prevalence was found for these urban communities. Taken both genders together, prevalence rates of HHV-8 antibody
increase gradually, across age-groups, ranging from 12.0% to 33.3%. When seroprevalence is analysed by gender, similar rates are
found for female (18.4%) and male (14.0%) individuals. In the former gender group, seroprevalence rates increased from 10.3%, in
children ≤ 10 years of age, to 30.0% in adults 41-50 years of age. Conversely, among male subjects, the prevalence of HHV-8
antibodies decreased from 13.3% in children/young adults aged ≤ 10 to 20 years of age to 6.1% in adults aged 21-30 years. From the
31-40 year-old group male onwards, seropositivity rates increased gradually, ranging from 8.3% to 66.7%. A significant difference in
seropositivity rates was noted when comparing 21-30 age groups for female and male subjects: 23.3% and 6.1%, respectively (P =
0.03). Geometric mean optical densities were found to increase slightly from the lower to the higher age-groups. Our data suggest that
transmission of HHV-8 occurs frequently in the general urban population of Belém, and that prevalence of antibody seems to increase
with age.
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INTRODUCTION
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma
herpesvirus (KSHV), was discovered by CHANG et al. (1994)13 as a
KS-specific DNA fragment. HHV-8 that belongs to the Rhadinovirus,
or gamma-2 herpesvirus, genus within the subfamily
Gammaherpesvirinae12,32.
HHV-8 DNA sequences have been detected in peripheral blood
lymphocytes of HIV-positive individuals with or without KS10,21,22,48, in
B-cell body cavity lymphomas9,18,37, in uroepithelial cells of healthy
immunocompetent individuals31, in HIV-1 negative patients with Bowen’s
disease21, in multicentric Castleman’s disease18,21, in prostate tissue and
in human semen7,20,31. HHV-8 has also been associated with other tumors,
including angiosarcomas, hemangiomas, malignant squamous cell
carcinomas and actinic keratosis23. This virus was also recently reported
to infect healthy blood donors5. The presence of HHV-8 DNA in tonsillar
swabs and saliva11,14,15 suggests that the virus replicates in tonsils and
then is sheds in saliva, which would contribute to HHV-8 transmission.
This was also observed for the others herpesviruses15,16 .
Seroepidemiological studies suggest that HHV-8 has two major
modes of transmission: sexual and non-sexual. The latter route of
transmission involves body fluids such as nasal secretions, saliva and
blood therefore explaining the ample distribution of HHV-8 in many
areas of the world5,6,24,28,38,43,45 .
HHV-8 is known to have a worldwide occurrence but infection rates
vary according to a combination of geographic and behavioural risk
factors2,37 . HHV-8 antibody titers among infected healthy adults were
found to be higher in regions with high HHV-8 seroprevalence rates and
where KS disease is common17,33. In African populations with high rates
of endemic KS, the prevalence of HHV-8 antibody in adults ranges from
30 to 60%1,33,40. In contrast, seroprevalence rates among healthy
heterosexual adults in North American and European populations are
reported to be generally low, of 1-2%17,39 . Intermediate prevalence rates
of HHV-8 antibodies among adults have been reported for Italy and
Greece (20-35%)9,42,44,46, whereas HHV-8 prevalence in Central American
and Caribbean populations has been reported to range between 10 and
29%19,25,41.
In Brazil, the prevalence of HHV-8 antibodies in the general
populations has not yet been established. Indeed, studies carried out to
date in Brazil have focussed on population groups that would theoretically
be at increased risk of acquiring HHV-8 infection. Two of these studies
have focussed on HHV-8 infection among HIV-positive patients with or
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without KS10,22,49. In this context, it has been demonstrated that the
prevalence of HHV-8 antibody is higher among HIV-1 infected gay men
with KS, as compared with other Brazilian groups. Of importance, an
epidemiological survey conducted by ZAGO et al.48, (2000) in
Southeastern Brazil yielded HHV-8 antibody rates to latent nuclear
antigens of 80% among HIV-positive patients with KS, whereas much
lower, but similar seropositivity rates, were found for HIV-positive
patients without KS (14.6%) and casualty patients (9.6%).
Recent seroepidemiological studies among remote Amerindian
communities living in Northern Brazil - using an immunofluorescence
test for latent antibody – showed an unusually high, overall 53%
prevalence. In addition to this, a new HHV-8 E subtype was found to be
hyperendemic in these Amerindians, although KS has not been reported
to occur among them3.
The present investigation dealt with the prevalence of HHV-8
antibody [immunoglobulin G class (IgG)] in normal populations
inhabiting two neighbouring, crowded districts of Belém, Northern
Brazil.
MATERIALS AND METHODS
The present study involved 81 low-income families – including 497
subjects – living in 2 neighbourhoods (“Guamá” and “Terra Firme”) of
Belém, Brazil. These families were randomly selected from records of a
previous rotavirus vaccine field trial conducted at the same site
(LINHARES, et al.26, 1996). Blood samples were drawn – by antecubital
venepuncture – from all individuals (n = 497) (236 of whom were male)
from August to December 1994. Infants aged less than six months were
not enrolled to participate in this study. Overall, ages ranged from 7
months to 70 years (mean, 18 years, SD = 15). All sera were stored
frozen, at – 20 ºC, until (anonymously) processed for the presence of
HHV-8 antibody.
Detection of IgG antibodies to HHV-8 was made using a commercial
enzyme-linked immunosorbent assay (ELISA) developed by
ADVANCED BIOTECHNOLOGIESTM (Columbia, Maryland, USA).
This is an assay that includes solid-phase multiple-well strips coated
with solubilized HHV-8 whole virus extract isolated from the KS-1 cell
line35. The KS-1 cell line is derived from a body cavity lymphoma, as
previously described36. Sera were tested at a (single) dilution of 1:100,
according to manufacturer’s instructions. ELISA results were calculated
dividing optical density (O.D.) values of serum samples by the mean
absorbance of cut-off. Serum samples yielding O.D. ratios of ≥ 1.00
were ranged as positive.
The data were analyzed using the EPI-INFO software version 6.0
(Atlanta, GA, USA). Rates were compared using the Mantel-Haenszel
chi-square test of association or Fisher’s exact test, when applicable.
Significance was defined as P < 0.05.
RESULTS
Overall, 16.3% (81/497) of tested persons had HHV-8 antibody, with
prevalence rates increasing from 12.0% to 33.3% across age groups (Table
1). Taking all age-groups together, similar seroprevalence rates were
found for women and men: 18.4% and 14.0%, respectively. Increasing
percentages of HHV-8 antibody were observed in women from the first
(10.3%) to the fifth age groups, and a comparatively low prevalence,
20%, was found among individuals over 50 years of age. Among male
subjects the prevalence of HHV-8 antibody decreased from 13.3%, in
children/young adults aged ≤ 10 to 20 years, to 6.1% in adults aged 21-
30 years. In the following age groups, 8.3% positivity was detected in
adults aged 31-40 years, rising to 66.7% in the age group > 50 years. A
significant difference in prevalences was detected when comparing female
and male individuals aged 21-30 years: 23.3% and 6.1%, respectively
(P = 0.03). Serum anti-HHV-8 IgG concentrations – as measured by
geometric mean optical densities (GMODs) according to age groups,
are shown in Table 2. GMOD values increased slightly from the first to
the fourth age groups (range, 1.5 to 1.9), decreasing across age-groups
of more than 40 years. Overall GMODs for Female tended to be higher
than those for Male: 1.8 and 1.5, respectively.
DISCUSSION
Recent studies2,17,35,37 have indicated a great variability in the HHV-
8 antibody prevalence in different geographic areas worldwide.
Serological and molecular studies suggest that HHV-8 may be largely
distributed in the human population and, like other herpesviruses, it has
Table 2
Distribution of geometric mean optical densities of HHV-8 antibody
according to age and gender in Belém, Pará, Brazil
             Geometric mean optical densities
Age (years)  Female  Male  Total
≤10a  1.5 (97)  1.6 (120) 1.5 (217)
11-20  1.8 (47)  1.5 (45) 1.7 (92)
21-30  1.9 (60)  1.3 (33) 1.8 (93)
31-40  1.9 (32)  2.3 (24) 1.9 (56)
41-50  2.0 (10)  1.2 (8) 1.5 (18)
> 50  1.7 (15)  1.9 (6) 1.8 (21)
Total  1.8 (261)  1.5 (236) 1.7 (497)
a All children in this age-group were older than 6 months.
Table 1
Prevalence of antibody to HHV-8 according to age and gender in Belém,
Pará, Brazil
          No. of sera positive/No. tested (%)
Age groups Total Female Male
(years)
≤ 10 26/217 (12.0%) 10/97 (10.3%) 16/120 (13.3%)
11- 20  16/92 (17.4%) 10/47 (21.3%)  6/45 (13.3%)
21- 30  16/93 (17.2%) 14/60 (23.3%)a  2/33 (6.1%)b
31- 40  10/56 (18.0%)  8/32 (25.0%)  2/24 (8.3%)
41- 50  6/18 (33.3%)  3/10 (30.0%)  3/8 (37.5%)
>50  7/21 (33.3%)  3/15 (20.0%)  4/6 (66.7%)
 Total    81/497 (16.3%)   48/261 (18.4%)    33/236 (14.0%)
a vs b Significant difference between prevalence rates (P = 0.03)
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the potential of infecting latently tissues and body fluids, until
reactivation4,11,25,27,38 . Worldwide, recent serosurveys indicate that HHV-
8 infection rates in various populations vary considerably, according to
a combination of geographic and behavioural factors2,17,35,37,38 . In Brazil,
very few studies have dealt with the epidemiology of HHV-8 infection
in the general population. In fact, most of these investigations have
focussed on specific, high-risk groups of the population, such as those
represented by HIV-seropositive individuals with or without KS10,22,48,49.
The goal of the present study was therefore to determine the
prevalence of HHV-8 antibodies in Belém, Brazil, regardless of the target
population’s HIV serological status. To our knowledge, this seems to be
the first approach in Northern Brazil aimed at assessing the immune
status of the general, urban population to HHV-849.
The overall HHV-8 seroprevalence (16.3%) in the Belém low-income,
urban communities is comparable to those observed for adult populations
in Italy and Greece18,37,42,46, where seropositivity rates averaged 19.5%.
These similarities suggest that both crowding and poor sanitation, which
are prevailing conditions in the resource poor study areas of Belém, do
not seem to enhance the potential for HHV-8 transmission, as already
demonstrated in previous studies. It should be pointed out, however,
that a few investigations propose a direct relationship between poor
socioeconomic condition and the potential for HHV-8 transmission29 .
Unlike the comparison made above, local seroprevalence rates were
much lower than those reported for endemic countries in Africa, as well
as for hyperendemic Brazilian Amerindian remote communities1,3,33,40.
The high prevalence in African countries might be explained by the fact
that HHV-8 infection rates generally parallel KS disease which is known
to be endemic in several parts of the continent, particularly East Africa.
Among hyperendemic Amerindian tribes, where KS has not been
reported, it has been postulated that transmission is probably oral rather
than sexual. Moreover, it has been hypothesized that Indians’ genetic
homogeneity may permit more frequent transmission of HHV-8 than
that in heterogeneous populations. Studies conducted in Southeastern
Brazil by ZAGO et al.48 (2000) found a 4.6% seroprevalence among
blood donors, a rate which is lower than that yielded for the urban
population of Belém, Brazil. Although such a difference may be related
to the use of different serological assays between studies under
comparison, it seems plausible to postulate that blood donor groups per
se are at an inherently lower risk of becoming infected by HHV-8 than is
the general population taken as a whole.
In this study, the overall prevalence rate of HHV-8 antibodies in
children aged ≤ 10 years (12.0%) was found to be lower, as compared
with data from several authors8,25,39. In spite of this, however, it can be
concluded that, in Belém, Brazil, a significant proportion of HHV-8
infection occurs during childhood, suggesting horizontal transmission,
perhaps among siblings, but also from mother to child34. The fact that
there are progressively increasing prevalence rates with increasing age
suggests endemicity of HHV-8 infection in the Belém urban communities.
In this context, it is most likely that transmission through sexual route
also play a role during adolescence and adulthood8,25,47 . It is noticeable
that antibody prevalence rate peaks - 33.3% - among adults aged ≥ 41
years, including the elderly, and this raises the question on whether HHV-
8 reactivation may occur in addition to the largely proposed sexual-
and- nonsexual routes of transmission, particularly among the oldest
persons4,11,22,30. Of note, in female subjects the pattern of antibody
acquisition by age is similar to that of both gender groups taken together;
however, among male individuals there was a significant decrease in
seroprevalence rates from the group of individuals aged ≤ 10-20 years
to that of 21-40 years. Although this may have occurred by chance,
mainly because of the small sample size, it could be hypothesized that
sexual route transmission might play a major role in the latter age group,
and men would be at lower risk of HHV-8 infection than women7 .
It was observed that seropositivity rate in female adults aged 21-30
years was significantly higher than that for male individuals clustered in
the same age group (P = 0.02). Although there is currently no well-
founded explanation for this difference, one can postulate that women
are at greater risk of HHV-8 infection, since this virus can be shed into
semen and might be transmitted during sexual intercourse7. Conversely,
shedding of HHV-8 into the genital tract of infected women is known to
be uncommon, suggesting that female-to-male transmission is probably
low47.
The progressive increase of geometric mean optical densities
(GMODs) across age-groups essentially reflects the pattern of antibody
acquisition as indicated by seroprevalence rates.
The results presented herein indicate that HHV-8 infection is endemic
in the urban population of Belém, Brazil. It is suggested that a significant
proportion of transmission occurs during childhood and that adult women
may be at greater risk of HHV-8 infection than men. Further local studies
are planned, focussing on the epidemiological features of HHV-8 infection
in high-risk groups, for example, HIV-infected persons with KS.
RESUMO
Prevalência de anticorpos para o herpesvírus humano tipo 8 na
população de Belém, Pará, Brasil
Amostras de soro de 497 crianças e adultos residentes em 2 bairros
(Terra Firme e Guamá) de Belém, Pará, norte do Brasil foram examinadas
com o propósito de detectar-se anticorpos para o herpesvírus 8, utilizando-
se a técnica imunoenzimática. A soroprevalência total nessas
comunidades urbanas foi de 16,3%. As taxas de prevalência de anticorpos
para o HHV-8, considerando ambos os sexos, aumentou progressivamente
através dos grupos de idade, variando de 12,0% a 33,3%. Quando a
soroprevalência é analisada por sexo, taxas similares são encontradas
para os indivíduos do sexo feminino (18,4%) e masculino (14,0%). A
taxa de prevalência no sexo feminino aumentou de 10,3%, em crianças
≤ 10 anos, para 30,0% nos adultos de 41-50 anos. Já nos indivíduos do
sexo masculino, a prevalência de anticorpos para o HHV-8 decresceu de
13,3%, nas crianças/adultos de ≤ 10 a 20 anos de idade, para 6,1% em
adultos com 21-30 anos. Do grupo etário de 31-40 anos para frente, as
taxas de soropositividade relativas ao sexo masculino aumentaram
gradualmente de 8,3% a 66,7%. Diferença significativa foi observada
nas taxas de soropositividade relacionadas ao grupo etário de 21-30 anos,
se comparados indivíduos dos sexos feminino e masculino: 23,3% e
6,1%, respectivamente (P = 0,03). A média geométrica das densidades
óticas aumentaram progressivamente do menor para o maior grupo de
idade. Nossos dados sugerem que a transmissão do HHV-8 ocorre com
frequência na população de Belém e que a prevalência de anticorpos
observada aumentou com a idade.
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